News Highlights: Top Company News of the Day
22 December 2023 - 1:30AM
Dow Jones News
Tesla Probed by Norwegian Roads Agency Over Suspension Failures
Tesla faces another potential recall after Norway's
traffic-safety regulator launched an inquiry into suspension
failures, the latest blow to hit the EV maker after it recalled 2
million vehicles earlier this month over problems with its
driver-assistance system.
Warner and Paramount CEOs Discussed Possible Merger of Companies
Warner Bros. Discovery CEO David Zaslav met Paramount CEO Bob
Bakish and discussed a possible merger between the media giants,
people familiar with the matter said-a deal that would unite some
of Hollywood and cable's biggest brands.
Why Peacock Is Giving Fans a Taste of the NFL Without Commercials
The streamer is expecting a lot of new viewers and wants to give
them an experience that will persuade them to become paying
subscribers.
Billionaires Compete to Own SpaceX's Rocket Rival
Blue Origin and Cerberus made buyout bids for a rocket launch
venture owned by Boeing and Lockheed Martin.
Wells Fargo Workers in Albuquerque Vote to Form Union, a First for a Megabank
Workers voted 5-3 in favor of unionizing, and those in other
branches have said they intend to hold votes. An Alaska branch is
expected to vote Thursday.
Nike Earnings Likely Won't Be Stellar. Analysts Are Still Excited About the Stock.
Analysts believe second-quarter revenue growth will be muted.
2024 could be much better.
Toyota Motor to Recall 1 Million Toyota, Lexus Models Over Airbag-Related Sensor
The automaker said six Toyota models and five Lexis models from
2020 to 2022 are included in the recall.
Startup Fauna Bio Studies Animal Genomes for Clues to Human Diseases
Fauna Bio compares genomic data from humans and other species to
find drug targets. Its obesity research with collaborator Eli Lilly
involves the 13-lined ground squirrel.
BlackBerry Loss Widens Despite Higher Revenue
The cybersecurity company posted a quarterly loss of $21
million, or 5 cents a share, compared with a loss of $4 million, or
1 cent a share, a year earlier. Revenue rose 3.6% to $175
million.
FDA Says Merck's Chronic Cough Treatment Didn't Show Substantial Evidence of Effectiveness
The pharmaceutical company said the FDA was responding to its
new drug application for gefapixant.
(END) Dow Jones Newswires
December 21, 2023 09:15 ET (14:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.